Different effects of adenosine and calcium channel blockade on myocardial no-reflow after acute myocardial infarction and reperfusion

Cardiovascular Drugs and Therapy

Volumn 20, Issue 3, 2006, Pages 167-175

  Zhao, Jing Lin ^a   Yang, Yue Jin ^a   Cui, Chuan Jue ^a   You, Shi Jie ^a   Wu, Yong Jian ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Acute myocardial infarction; Adenosine; Calcium channel blockade; No reflow; Reperfusion; Vasodilator

Indexed keywords

ADENOSINE; BETA CATENIN; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; PLAKOGLOBIN; VASCULAR ENDOTHELIAL CADHERIN; VERAPAMIL;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ECHOCARDIOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HISTOPATHOLOGY; IN VIVO STUDY; MINIPIG; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; TISSUE PERFUSION;

ADENOSINE; ANIMALS; ANTIGENS, CD; BETA CATENIN; CADHERINS; CALCIUM CHANNEL BLOCKERS; CORONARY CIRCULATION; GAMMA CATENIN; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RNA, MESSENGER; SWINE; SWINE, MINIATURE;

EID: 33746266470     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-8284-9     Document Type: Article

References (42)

1. Gersh BJ. Optimal management of acute myocardial infarction at the turn of the next millennium. Am Heart J 1999;138:188-202.
2. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993-9.
3. van 't Hof AW, Liem A, de Boer MJ, et al. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet 1997;350:615-9.
4. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no-reflow' phenomenon: a predictor of complications and left ventricular remodeling in perfused anterior wall myocardial infarction. Circulation 1996;93:223-8.
5. Reffelmann T, Hale SL, Dow JS, et al. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation 2003;108:2911-7.
6. Ragosta M, Camarano G, Kaul S, et al. Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction. New insights using myocardial contrast echocardiography. Circulation 1994;89:2562-9.
7. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-72.
8. Swinburn JM, Lahiri A, Senior R. Intravenous myocardial contrast echocardiography predicts recovery of dysynergic myocardium early after acute myocardial infarction. J Am Coll Cardiol 2001;38:19-25.
9. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart 2002;87:162-8.
10. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-9.
11. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no-reflow phenomenon." Catheter Cardiovasc Interv 2000;51:27-31.
12. Kopecky SL, Aviles RJ, Bell MR, et al. A randomized double blinded placebo controlled, dose ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary PTCA. The ADMIRE (AmP579 delivery for myocardial infarction Reduction) study. Am Heart J 2003;146:146-52.
13. Quintana M, Hjemdahl P, Sollevi A, et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 2003;59:1-9.
14. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34:1711-20.
15. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30:1193-9.
16. Freireich EJ, Gehan DP, Rail LH, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
17. Bae RY, Belohlavek M, Greenleaf. Myocardial contrast echocardiography: texture analysis for identification of non-perfused versus perfused myocardium. Echocardiography 2001;18:665-72.
18. Yang Y, Li SQ, Peter B, et al. Effects of hypoxia on coronary flow reserve as determined by myocardial contrast echocardiography in swine. Chin Med J (Engl) 2004;117:1453-8.
19. Coggins MP, Sklener J, Lee DE, et al. Noninvasive prediction of ultimate infarct size at the time of acute coronary occlusion based on the extent and magnitude of collateral-derived myocardial blood flow. Circulation 2001;104:2471-7.
20. Kunichika H. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 2004;43:276-3.
21. Bradford. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
22. Reffelmann T, Kloner RA. Effects of adenosine and verapamil on anatomic no-reflow in a rabbit model of coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 2004;43:580-8.
23. Donato M, Gelpi RJ. Adenosine and cardioprotection during reperfusion - an overview. Mol Cell Biochem 2003;251:153-9.
24. Kloner RA, Ganote CE, Jennings RB. The no-reflow phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1498-508.
25. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983;111:98-111.
26. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-62.
27. Hori M, Kitakaze. Adenosine, heart and coronary circulation. Hypertension 1991;18:565-74.
28. Norton ED, Jackson EK. The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury. Am Heart J 1992;123:332-8.
29. Olafsson B, Forman MB, Puett DW, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 1987;76:1135-45.
30. Galiuto L. Optimal therapeutic strategies in the setting of post-infarc no reflow: the need for a pathogenetic classification. Heart 2004;90:123-5.
31. Asanuma T, Tanabe K, Ochiai K, et al. Relationship between progressive microvascular damage and intramyocardial hemorrhage in patients with reperfused anterior myocardial infarction. Circulation 1997;96:448-53.
32. Fishbein MC, Y-Rit J, Lando U, et al. The relationship of vascular injury and myocardial hemorrhage to necrosis after reperfusion. Circulation 1980;62:1274-9.
33. Dejana E. Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest 1996;98:1949-53.
34. Corada M, Mariotti M, Thurston G, et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci USA 1999;96:9815-20.
35. Dejana E. Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest 1997;100:S7-10.
36. Finegan BA, Lopaschuk GD. Adenosine alters glucose use during ischemia and reperfusion in isolated rat hearts. Circulation 1993;87:900-8.
37. Tadokoro H, Miyazaki A, Satomura K. Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occlusion/reperfusion porcine heart model. J Cardiovasc Pharmacol 1996;28:134-41.
38. Higginson L, Tang A, Knoll G. Effect of intracoronary diltiazem on infarct size and regional myocardial function in the ischemic reperfused canine heart. J Am Coll Cardiol 1991;18:868-75.
39. Gao F, Christopher TA, Lopez BL, et al. Mechanism of decreased adenosine protection in reperfusion injury of aging rats. Am J Physiol Heart Circ Physiol 2000;279:H329-38.
40. Wasir H, Bhan A, Choudhary SK, et al. Pretreatment of human myocardium with adenosine. Eur J Cardiothorac Surg 2001;19:41-6.
41. Herzog WR, Vogel RA, Schlossberg ML, et al. Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size. Int J Cardiol 1997;59:21-7.
42. Przyklenk K, Kloner RA. Effect of verapamil on postischemic "stunned" myocardium: importance of the timing of treatment. J Am Coll Cardiol 1988;11:614-23.